Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DUP48T
|
|||
| Drug Name |
SPR741
|
|||
| Synonyms |
1179330-52-9; NAB741; CHEMBL1631770; SCHEMBL21116156; SPR-741; SPR741 (NAB741); EX-A4067; HY-P1649; CS-0079940; (2S,3R)-2-acetamido-3-hydroxy-N-[(2R)-3-hydroxy-1-oxo-1-[[(3S,6S,9S,12S,15R,18S,21S)-6,9,18-tris(2-aminoethyl)-15-benzyl-3-[(1R)-1-hydroxyethyl]-12-(2-methylpropyl)-2,5,8,11,14,17,20-heptaoxo-1,4,7,10,13,16,19-heptazacyclotricos-21-yl]amino]propan-2-yl]bu
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Acinetobacter baumannii infection [ICD-11: CA40.0Y] | Phase 1 | [1] | |
| Company |
Spero Therapeutics
|
|||
| Structure |
 |
Download2D MOL
|
||
| Formula |
C44H73N13O13
|
|||
| Canonical SMILES |
CC(C)CC1C(=O)NC(C(=O)NC(C(=O)NC(C(=O)NCCC(C(=O)NC(C(=O)NC(C(=O)N1)CC2=CC=CC=C2)CCN)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C)C(C)O)CCN)CCN
|
|||
| InChI |
1S/C44H73N13O13/c1-22(2)19-31-40(66)52-27(11-15-45)36(62)51-29(13-17-47)39(65)57-34(23(3)59)43(69)48-18-14-30(53-42(68)33(21-58)56-44(70)35(24(4)60)49-25(5)61)38(64)50-28(12-16-46)37(63)55-32(41(67)54-31)20-26-9-7-6-8-10-26/h6-10,22-24,27-35,58-60H,11-21,45-47H2,1-5H3,(H,48,69)(H,49,61)(H,50,64)(H,51,62)(H,52,66)(H,53,68)(H,54,67)(H,55,63)(H,56,70)(H,57,65)/t23-,24-,27+,28+,29+,30+,31+,32-,33-,34+,35+/m1/s1
|
|||
| InChIKey |
JBFNEVNUGGFPBQ-DDMCRLCFSA-N
|
|||
| PubChem Compound ID | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03022175) A First in Human Study of the Safety and Tolerability of Single and Multiple Doses of SPR741 in Healthy Volunteers. U.S. National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.